XTL Biopharmaceuticals Ltd. (XTLB) Income Statement
XTLB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsXTLB revenue and net income
XTLB profit margins
XTLB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −100.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XTLB quarterly EPS vs estimates
XTL Biopharmaceuticals beat the analyst EPS estimate in 1 of the last 4 quarters.
XTLB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $451,000 | $0 | $0 | $1.5M | $28,000 | $69,000 | $52,000 | $29,000 | $23,000 |
| Cost of revenue | $0 | $448,000 | $0 | $1,000 | $1,000 | $1,000 | $0 | $0 | $1,000 | $3,000 |
| Gross profit | $0 | $3,000 | $0 | −$1,000 | −$1,000 | −$1,000 | $69,000 | $52,000 | $28,000 | $20,000 |
| Research & development | $28,000 | $98,000 | $31,000 | $30,000 | $30,000 | $38,000 | $35,000 | $38,000 | $43,000 | $443,000 |
| Sales, general & admin | $1.1M | $2.0M | $734,000 | $850,000 | $1.0M | $910,000 | $807,000 | $755,000 | $1.2M | $1.3M |
| Total operating expenses | $1.7M | $2.2M | $765,000 | $880,000 | $1.0M | $948,000 | $842,000 | $793,000 | $1.2M | $1.7M |
| Operating income | −$1.7M | −$2.2M | −$765,000 | −$880,000 | −$1.0M | −$948,000 | −$842,000 | −$793,000 | −$1.2M | −$2.6M |
| Interest income | $60,000 | $34,000 | $46,000 | $36,000 | $8,000 | $33,000 | $93,000 | $87,000 | $16,000 | $0 |
| Interest expense | $7,000 | $86,000 | $3,999 | $10,999 | $21,000 | $16,999 | $29,000 | $7,000 | $8,000 | $16,000 |
| Income before taxes | −$759,000 | −$1.2M | −$1.8M | −$1.3M | $435,000 | −$3.0M | −$1.3M | $3.0M | −$781,000 | −$2.5M |
| Income taxes | — | −$130,000 | −$167,894 | $468,000 | −$1.5M | −$166,000 | −$69,000 | −$80,000 | −$457,000 | $832,000 |
| Net income | −$7.0M | −$1.0M | −$1,782 | −$1.3M | $435,000 | −$782,000 | −$1.3M | $3.0M | −$781,000 | −$2.5M |
| EBITDA | −$752,000 | −$930,000 | −$764,000 | −$879,000 | −$1.0M | −$947,000 | −$268,000 | −$792,000 | −$1.2M | −$1.7M |
| EPS (diluted) | −$0.01 | −$0.20 | −$0.33 | −$0.33 | $0.24 | −$0.01 | $0.00 | $0.01 | $0.31 | −$0.14 |
| Gross margin | — | 0.7% | — | — | −0.1% | −3.6% | 100.0% | 100.0% | 96.6% | 87.0% |
| Operating margin | — | −481.6% | — | — | −70.3% | −3,385.7% | −1,220.3% | −1,525.0% | −4,296.6% | −11,134.8% |
| Net margin | — | −227.7% | — | — | 29.7% | −2,792.9% | −1,952.2% | 5,742.3% | −2,693.1% | −11,065.2% |
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $289,000 | $289,000 | $162,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $332,000 | $332,000 | $116,000 | — | — | — | — | — | — | $459,000 | — | — |
| Gross profit | −$43,000 | −$43,000 | $162,000 | — | — | — | — | — | — | −$459,000 | — | — |
| Research & development | $32,000 | $32,000 | $54,000 | $6,000 | $6,000 | $6 | $6,000 | $6,000 | $13,000 | $6,000 | $3,000 | $15,000 |
| Sales, general & admin | $812,000 | $706,000 | $756,000 | $415,000 | $169,000 | $194 | $145,000 | $157,000 | $238,000 | $219,000 | $201,000 | $187,000 |
| Total operating expenses | $769,000 | $1.1M | $926,000 | $421,000 | $175,000 | $333 | $151,000 | $163,000 | $251,000 | $225,000 | $204,000 | $202,000 |
| Operating income | −$812,000 | −$812,000 | −$764,000 | −$421,000 | −$175,000 | −$200 | −$151,000 | −$163,000 | −$251,000 | −$225,000 | −$204,000 | −$202,000 |
| Interest income | — | $2,000 | $13,000 | $9,000 | $10,000 | $11,000 | $9,000 | $9,000 | $12,000 | $16,000 | — | $5,000 |
| Interest expense | $36,000 | $94,000 | $93,000 | $13,000 | $16,000 | — | $28,000 | $32,000 | $25,000 | $30,000 | $10,000 | $11,000 |
| Income before taxes | −$385,000 | −$385,000 | −$553,000 | −$704,000 | $485,000 | −$284 | −$215,000 | −$364,000 | −$919,000 | −$748,000 | −$821,000 | −$285,000 |
| Income taxes | −$130,000 | — | — | — | $931,999 | −$43,812 | $19,000 | $23,000 | $13,000 | −$27,000 | −$10,000 | $6,000 |
| Net income | −$255,000 | −$255,000 | −$553,000 | −$704,000 | $485,000 | −$284 | −$215,000 | −$364,000 | −$919,000 | −$748,000 | −$821,000 | −$285,000 |
| EBITDA | −$429,250 | −$479,000 | $304,000 | −$691,000 | $659,999 | −$199,750 | −$186,750 | −$331,750 | −$893,749 | −$224,750 | −$895,750 | −$273,750 |
| EPS (diluted) | $0.00 | −$0.12 | −$0.04 | −$0.13 | $0.09 | −$0.05 | −$0.04 | −$0.07 | −$0.17 | −$0.14 | −$0.15 | −$0.05 |
| Gross margin | −14.9% | −14.9% | 100.0% | — | — | — | — | — | — | — | — | — |
| Operating margin | −281.0% | −281.0% | −471.6% | — | — | — | — | — | — | — | — | — |
| Net margin | −88.2% | −88.2% | −341.4% | — | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XTLB's financial statements (latest annual report filed June 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XTLB financial results
XTL Biopharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $7.0 million. Diluted earnings per share came to −$0.01.
See the XTLB stock overview for the latest quote and news, or the XTLB chart for price history and technical indicators.
XTLB income statement FAQ
Does XTL Biopharmaceuticals have revenue?
XTL Biopharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is XTL Biopharmaceuticals profitable?
No. XTL Biopharmaceuticals reported a net loss of $7.0 million in fiscal 2025.
How much does XTL Biopharmaceuticals spend on research and development?
XTL Biopharmaceuticals spent $0.0 million on research and development in fiscal 2025.
What are XTL Biopharmaceuticals's earnings per share?
XTL Biopharmaceuticals earned $-0.01 per diluted share in fiscal 2025, compared with $-0.20 a year earlier.
When does XTL Biopharmaceuticals's fiscal year end?
XTL Biopharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on June 30, 2026.